🚀 VC round data is live in beta, check it out!
Candel Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Candel Therapeutics and similar public comparables like Racura Oncology, Immuneering, Greenwich LifeSciences, Cabaletta Bio and more.
Candel Therapeutics Overview
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Founded
2003
HQ
Employees
42
Website
Sectors
Financials (LTM)
EV
$283M
Candel Therapeutics Financials
Candel Therapeutics reported last 12-month revenue of — and negative EBITDA of ($55M).
In the same LTM period, Candel Therapeutics generated ($55M) in EBITDA losses and had net loss of ($50M).
Revenue (LTM)
Candel Therapeutics P&L
In the most recent fiscal year, Candel Therapeutics reported revenue of — and EBITDA of ($35M).
Candel Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($55M) | XXX | ($35M) | XXX | XXX | XXX |
| Net Profit | ($50M) | XXX | ($38M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Candel Therapeutics Stock Performance
Candel Therapeutics has current market cap of $354M, and enterprise value of $283M.
Market Cap Evolution
Candel Therapeutics' stock price is $4.83.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $283M | $354M | 0.3% | XXX | XXX | XXX | $-0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCandel Therapeutics Valuation Multiples
Candel Therapeutics trades at (5.1x) EV/EBITDA.
EV / Revenue (LTM)
Candel Therapeutics Financial Valuation Multiples
As of April 11, 2026, Candel Therapeutics has market cap of $354M and EV of $283M.
Equity research analysts estimate Candel Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Candel Therapeutics has a P/E ratio of (7.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $354M | XXX | $354M | XXX | XXX | XXX |
| EV (current) | $283M | XXX | $283M | XXX | XXX | XXX |
| EV/EBITDA | (5.1x) | XXX | (8.0x) | XXX | XXX | XXX |
| EV/EBIT | (5.1x) | XXX | (5.9x) | XXX | XXX | XXX |
| P/E | (7.1x) | XXX | (9.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Candel Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Candel Therapeutics Margins & Growth Rates
Candel Therapeutics' revenue in the last fiscal year grew by —.
Candel Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Candel Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 21% | XXX | 111% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Candel Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Racura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| Greenwich LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Cabaletta Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Rezolute | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Candel Therapeutics M&A Activity
Candel Therapeutics acquired XXX companies to date.
Last acquisition by Candel Therapeutics was on XXXXXXXX, XXXXX. Candel Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Candel Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCandel Therapeutics Investment Activity
Candel Therapeutics invested in XXX companies to date.
Candel Therapeutics made its latest investment on XXXXXXXX, XXXXX. Candel Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Candel Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Candel Therapeutics
| When was Candel Therapeutics founded? | Candel Therapeutics was founded in 2003. |
| Where is Candel Therapeutics headquartered? | Candel Therapeutics is headquartered in United States. |
| How many employees does Candel Therapeutics have? | As of today, Candel Therapeutics has over 42 employees. |
| Who is the CEO of Candel Therapeutics? | Candel Therapeutics' CEO is Paul Peter Tak. |
| Is Candel Therapeutics publicly listed? | Yes, Candel Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Candel Therapeutics? | Candel Therapeutics trades under CADL ticker. |
| When did Candel Therapeutics go public? | Candel Therapeutics went public in 2021. |
| Who are competitors of Candel Therapeutics? | Candel Therapeutics main competitors are Racura Oncology, Immuneering, Greenwich LifeSciences, Cabaletta Bio. |
| What is the current market cap of Candel Therapeutics? | Candel Therapeutics' current market cap is $354M. |
| Is Candel Therapeutics profitable? | No, Candel Therapeutics is not profitable. |
| What is the current EBITDA of Candel Therapeutics? | Candel Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Candel Therapeutics? | Current EBITDA multiple of Candel Therapeutics is (5.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.